Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer
Dr Sanjit Kumar Agrawal speaks to ecancer about therapeutic mammoplasty, an advanced oncoplastic breast surgery technique that integrates effective tumour removal with immediate breast reshaping.
This approach allows surgeons to achieve clear oncological margins while delivering significantly improved cosmetic outcomes compared with standard breast conserving surgery.
Particularly suited for patients with larger or denser breasts and higher tumour to breast volume ratios, therapeutic mammoplasty expands eligibility for breast conservation while also enhancing postoperative symmetry and overall quality of life.
In this presentation, Dr Agrawal outlines key surgical techniques, patient selection considerations, and strategies for managing complications.
He also shares real world outcome data from his institutional audit, demonstrating the safety, effectiveness, and aesthetic benefits of this evolving approach in modern breast cancer care.
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC
Screen-detectable cancers account for majority of early-onset cancer cases under age 50
ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer